{"id":"W2987946496","doi":"10.1093/neuonc/noz175.073","title":"ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Trametinib; Medicine; Dabrafenib; Internal medicine; Oncology; Glioma; Progression-free survival; Discontinuation; Interim analysis; Clinical endpoint; MEK inhibitor; Clinical trial; Chemotherapy; Cancer; Cancer research; MAPK/ERK pathway; Vemurafenib; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002848842,0.0004622487,0.001235329,0.0004453084,0.00006411782,0.00001863901,0.0001454687,0.0003147137,0.0002754702],"category_scores_gemma":[0.0001636502,0.0003568645,0.00007958406,0.0006280519,0.0003275166,0.000136466,0.0001228512,0.0005703884,0.00002657393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002328014,"about_ca_system_score_gemma":0.0002803008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001296845,"about_ca_topic_score_gemma":0.00004517137,"domain_scores_codex":[0.9969161,0.0005044464,0.0007528417,0.0008413763,0.0004039878,0.0005812516],"domain_scores_gemma":[0.9977912,0.0007942563,0.0004225833,0.0005240886,0.0001210348,0.0003468725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.08294132,0.03350361,0.3022159,0.001437365,0.002398062,0.006417091,0.004515581,0.000176044,0.3563801,0.0007254829,0.002785828,0.2065036],"study_design_scores_gemma":[0.1209703,0.02518552,0.8251094,0.0002985558,0.0007082343,0.0004359131,0.0002065663,0.0002603084,0.01373929,0.00004678696,0.01245329,0.000585812],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958153,0.000318632,0.000005213864,0.001055534,0.000365533,0.002067508,0.0001407383,0.00006977328,0.0001618119],"genre_scores_gemma":[0.9984033,0.0001217689,0.0004706758,0.0003990704,0.0000475022,0.00003041946,0.000442539,0.00007084013,0.00001394474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5228935,"threshold_uncertainty_score":0.9998884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01139772099240635,"score_gpt":0.2691038434296475,"score_spread":0.2577061224372412,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}